{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T10:57:54Z","timestamp":1785495474252,"version":"3.56.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,4,19]],"date-time":"2025-04-19T00:00:00Z","timestamp":1745020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,4,19]],"date-time":"2025-04-19T00:00:00Z","timestamp":1745020800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2025,6,29]]},"DOI":"10.1038\/s41416-025-02998-3","type":"journal-article","created":{"date-parts":[[2025,4,19]],"date-time":"2025-04-19T16:03:17Z","timestamp":1745078597000},"page":"1177-1187","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Unveiling the BRAF fusion structure variations through DNA and RNA sequencing"],"prefix":"10.1038","volume":"132","author":[{"given":"Qiong","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baoming","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuli","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5414-0522","authenticated-orcid":false,"given":"Tonghui","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenyuan","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xufan","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaochen","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qifeng","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianyao","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Houquan","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yangyang","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3483-1817","authenticated-orcid":false,"given":"Jianzhong","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4211-7237","authenticated-orcid":false,"given":"Zaiyuan","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,19]]},"reference":[{"key":"2998_CR1","doi-asserted-by":"publisher","first-page":"1618","DOI":"10.3390\/cancers11101618","volume":"11","author":"C Braicu","year":"2019","unstructured":"Braicu C, Buse M, Busuioc C, Drula R, Gulei D, Raduly L, et al. A comprehensive review on MAPK: a promising therapeutic target in cancer. Cancers. 2019;11:1618.","journal-title":"Cancers"},{"key":"2998_CR2","doi-asserted-by":"publisher","first-page":"4618","DOI":"10.1158\/1078-0432.CCR-21-2138","volume":"28","author":"PI Poulikakos","year":"2022","unstructured":"Poulikakos PI, Sullivan RJ, Yaeger R. Molecular pathways and mechanisms of BRAF in cancer therapy. Clin Cancer Res. 2022;28:4618\u201328.","journal-title":"Clin Cancer Res"},{"key":"2998_CR3","doi-asserted-by":"publisher","first-page":"4023","DOI":"10.1200\/JCO.2015.63.2471","volume":"33","author":"RB Corcoran","year":"2015","unstructured":"Corcoran RB, Atreya CE, Falchook GS, Kwak EL, Ryan DP, Bendell JC, et al. Combined BRAF and MEK inhibition with dabrafenib and trametinib in BRAF V600\u2013mutant colorectal cancer. J Clin Oncol. 2015;33:4023\u201331.","journal-title":"J Clin Oncol"},{"key":"2998_CR4","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1016\/S1470-2045(15)00087-X","volume":"16","author":"JJ Grob","year":"2015","unstructured":"Grob JJ, Amonkar MM, Karaszewska B, Schachter J, Dummer R, Mackiewicz A, et al. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial. Lancet Oncol. 2015;16:1389\u201398.","journal-title":"Lancet Oncol"},{"key":"2998_CR5","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1111\/j.1750-3639.2010.00454.x","volume":"21","author":"A Von Deimling","year":"2011","unstructured":"Von Deimling A, Korshunov A, Hartmann C. The next generation of glioma biomarkers: MGMT methylation, BRAF fusions and IDH1 mutations. Brain Pathol. 2011;21:74\u201387.","journal-title":"Brain Pathol"},{"key":"2998_CR6","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-023-00359-y","volume":"7","author":"KC Schreck","year":"2023","unstructured":"Schreck KC, Langat P, Bhave VM, Li T, Woodward E, Pratilas CA, et al. Integrated molecular and clinical analysis of BRAF-mutant glioma in adults. NPJ Precis Oncol. 2023;7:23.","journal-title":"NPJ Precis Oncol"},{"key":"2998_CR7","doi-asserted-by":"publisher","first-page":"4790","DOI":"10.1158\/1078-0432.CCR-11-0034","volume":"17","author":"C Hawkins","year":"2011","unstructured":"Hawkins C, Walker E, Mohamed N, Zhang C, Jacob K, Shirinian M, et al. BRAF-KIAA1549 fusion predicts better clinical outcome in pediatric low-grade astrocytoma. Clin Cancer Res. 2011;17:4790\u20138.","journal-title":"Clin Cancer Res"},{"key":"2998_CR8","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1002\/ijc.29825","volume":"138","author":"JS Ross","year":"2016","unstructured":"Ross JS, Wang K, Chmielecki J, Gay L, Johnson A, Chudnovsky J, et al. The distribution of BRAF gene fusions in solid tumors and response to targeted therapy. Int J Cancer. 2016;138:881\u201390.","journal-title":"Int J Cancer"},{"key":"2998_CR9","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1016\/j.jtho.2018.05.027","volume":"13","author":"AB Schrock","year":"2018","unstructured":"Schrock AB, Zhu VW, Hsieh W-S, Madison R, Creelan B, Silberberg J, et al. Receptor tyrosine kinase fusions and BRAF kinase fusions are rare but actionable resistance mechanisms to EGFR tyrosine kinase inhibitors. J Thorac Oncol. 2018;13:1312\u201323.","journal-title":"J Thorac Oncol"},{"key":"2998_CR10","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1158\/1078-0432.CCR-20-3208","volume":"27","author":"S-R Yang","year":"2021","unstructured":"Yang S-R, Aypar U, Rosen EY, Mata DA, Benayed R, Mullaney K, et al. A performance comparison of commonly used assays to detect RET fusions. Clin Cancer Res. 2021;27:1316\u201328.","journal-title":"Clin Cancer Res"},{"key":"2998_CR11","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/j.jmoldx.2018.05.007","volume":"20","author":"SW Lam","year":"2018","unstructured":"Lam SW, Cleton-Jansen A-M, Cleven AH, Ruano D, van Wezel T, Szuhai K, et al. Molecular analysis of gene fusions in bone and soft tissue tumors by anchored multiplex PCR\u2013based targeted next-generation sequencing. J Mol Diagn. 2018;20:653\u201363.","journal-title":"J Mol Diagn"},{"key":"2998_CR12","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1093\/neuonc\/nov289","volume":"18","author":"MN Nikiforova","year":"2015","unstructured":"Nikiforova MN, Wald AI, Melan MA, Roy S, Zhong S, Hamilton RL, et al. Targeted next-generation sequencing panel (GlioSeq) provides comprehensive genetic profiling of central nervous system tumors. Neuro-Oncol. 2015;18:379\u201387.","journal-title":"Neuro-Oncol"},{"key":"2998_CR13","doi-asserted-by":"publisher","first-page":"2200","DOI":"10.1002\/1878-0261.13509","volume":"17","author":"S Zhou","year":"2023","unstructured":"Zhou S, Zhang F, Xu M, Zhang L, Liu Z, Yang Q, et al. Novel insights into molecular patterns of ROS1 fusions in a large Chinese NSCLC cohort: a multicenter study. Mol Oncol. 2023;17:2200\u201312.","journal-title":"Mol Oncol"},{"key":"2998_CR14","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.jtho.2020.12.006","volume":"16","author":"Z Song","year":"2021","unstructured":"Song Z, Lu C, Xu C-W, Zheng Z. Noncanonical gene fusions detected at the DNA level necessitate orthogonal diagnosis methods before targeted therapy. J Thorac Oncol. 2021;16:344\u20138.","journal-title":"J Thorac Oncol"},{"key":"2998_CR15","doi-asserted-by":"crossref","unstructured":"Li Y, Wang B, Wang C, Zhao D, Liu Z, Niu Y, et al. Genomic and transcriptional profiling of Chinese melanoma patients enhanced potentially druggable targets: a multicenter study. Cancers. 2022;15:283.","DOI":"10.3390\/cancers15010283"},{"key":"2998_CR16","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1093\/bioinformatics\/btu170","volume":"30","author":"AM Bolger","year":"2014","unstructured":"Bolger AM, Lohse M, Usadel B. Trimmomatic: a flexible trimmer for Illumina sequence data. Bioinformatics. 2014;30:2114\u201320.","journal-title":"Bioinformatics"},{"key":"2998_CR17","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1138100","volume":"14","author":"J Zhou","year":"2023","unstructured":"Zhou J, Wang WR, Zhang HF, Gao QQ, Wang WB, Zhu JH, et al. Molecular and clinical features of papillary thyroid cancer in adult patients with a non-classical phenotype. Front Endocrinol. 2023;14:1138100.","journal-title":"Front Endocrinol"},{"key":"2998_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-022-02362-9","volume":"20","author":"W Li","year":"2022","unstructured":"Li W, Wan R, Guo L, Chang G, Jiang D, Meng L, et al. Reliability analysis of exonic-breakpoint fusions identified by DNA sequencing for predicting the efficacy of targeted therapy in non-small cell lung cancer. BMC Med. 2022;20:160.","journal-title":"BMC Med"},{"key":"2998_CR19","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1002\/1878-0261.13348","volume":"17","author":"Z Wang","year":"2023","unstructured":"Wang Z, Han Y, Tao H, Xu M, Liu Z, Zhu J, et al. Molecular characterization of genomic breakpoints of ALK rearrangements in non-small cell lung cancer. Mol Oncol. 2023;17:765\u201378.","journal-title":"Mol Oncol"},{"key":"2998_CR20","doi-asserted-by":"crossref","unstructured":"Ma F, Zhao Y, Wang C, Han T, Ding R, Deng W, et al. The analysis of BRAF fusions characteristics in Chinese solid tumor patients. J Clin Oncol. 2023;41:e15073-e15073.","DOI":"10.1200\/JCO.2023.41.16_suppl.e15073"},{"key":"2998_CR21","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1016\/j.cell.2015.05.044","volume":"161","author":"R Akbani","year":"2015","unstructured":"Akbani R, Akdemir K, \u00e1Arman Aksoy B, Albert M, Ally A, Amin S, et al. Genomic classification of cutaneous melanoma. Cell. 2015;161:1681\u201396.","journal-title":"Cell"},{"key":"2998_CR22","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.jtho.2020.10.156","volume":"16","author":"W Li","year":"2021","unstructured":"Li W, Guo L, Liu Y, Dong L, Yang L, Chen L, et al. Potential unreliability of uncommon ALK, ROS1, and RET genomic breakpoints in predicting the efficacy of targeted therapy in NSCLC. J Thorac Oncol. 2021;16:404\u201318.","journal-title":"J Thorac Oncol"},{"key":"2998_CR23","doi-asserted-by":"publisher","DOI":"10.1177\/1758835919856494","volume":"11","author":"M Ducreux","year":"2019","unstructured":"Ducreux M, Chamseddine A, Laurent-Puig P, Smolenschi C, Hollebecque A, Dartigues P, et al. Molecular targeted therapy of BRAF-mutant colorectal cancer. Ther Adv Med Oncol. 2019;11:1758835919856494.","journal-title":"Ther Adv Med Oncol"},{"key":"2998_CR24","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/s41379-019-0324-7","volume":"33","author":"JP Solomon","year":"2020","unstructured":"Solomon JP, Linkov I, Rosado A, Mullaney K, Rosen EY, Frosina D, et al. NTRK fusion detection across multiple assays and 33,997 cases: diagnostic implications and pitfalls. Mod Pathol. 2020;33:38\u201346.","journal-title":"Mod Pathol"},{"key":"2998_CR25","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1016\/j.jtho.2020.02.023","volume":"15","author":"W Li","year":"2020","unstructured":"Li W, Liu Y, Li W, Chen L, Ying J. Intergenic breakpoints identified by DNA sequencing confound targetable kinase fusion detection in NSCLC. J Thorac Oncol. 2020;15:1223\u201331.","journal-title":"J Thorac Oncol"},{"key":"2998_CR26","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1097\/JTO.0000000000000311","volume":"9","author":"T Kodama","year":"2014","unstructured":"Kodama T, Motoi N, Ninomiya H, Sakamoto H, Kitada K, Tsukaguchi T, et al. A novel mechanism of EML4-ALK rearrangement mediated by chromothripsis in a patient-derived cell line. J Thorac Oncol. 2014;9:1638\u201346.","journal-title":"J Thorac Oncol"},{"key":"2998_CR27","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.canlet.2013.01.011","volume":"340","author":"MJ Annala","year":"2013","unstructured":"Annala MJ, Parker BC, Zhang W, Nykter M. Fusion genes and their discovery using high throughput sequencing. Cancer Lett. 2013;340:192\u2013200.","journal-title":"Cancer Lett"},{"key":"2998_CR28","doi-asserted-by":"publisher","first-page":"2581","DOI":"10.1093\/nar\/29.12.2581","volume":"29","author":"TA Thanaraj","year":"2001","unstructured":"Thanaraj TA, Clark F. Human GC-AG alternative intron isoforms with weak donor sites show enhanced consensus at acceptor exon positions. Nucleic Acids Res. 2001;29:2581\u201393.","journal-title":"Nucleic Acids Res"},{"key":"2998_CR29","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.70191","volume":"13","author":"J Feng","year":"2024","unstructured":"Feng J, Ma T, Wang C, Wang B, Liu Q, Liu Z, et al. Clinical relevance and druggability of sole reciprocal kinase fusions: a large-scale study. Cancer Med. 2024;13:e70191.","journal-title":"Cancer Med"},{"key":"2998_CR30","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1038\/modpathol.2017.181","volume":"31","author":"JN Rosenbaum","year":"2018","unstructured":"Rosenbaum JN, Bloom R, Forys JT, Hiken J, Armstrong JR, Branson J, et al. Genomic heterogeneity of ALK fusion breakpoints in non-small-cell lung cancer. Mod Pathol. 2018;31:791\u2013808.","journal-title":"Mod Pathol"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41416-025-02998-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-025-02998-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-025-02998-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T11:55:29Z","timestamp":1749556529000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-025-02998-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,19]]},"references-count":30,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,6,29]]}},"alternative-id":["2998"],"URL":"https:\/\/doi.org\/10.1038\/s41416-025-02998-3","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,19]]},"assertion":[{"value":"18 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 April 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"BMW and THM were employed by Genecn-Biotech Co.Ltd, Hangzhou, Zhejiang, China.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}